• Evaxion plans to use new preclinical results to finalize antigen selection for its EVX-V1 cytomegalovirus vaccine candidate.
• The data is intended to support a broadly protective, next-generation multi-component CMV vaccine combining AI-discovered antigens with AI-optimized established antigens.
• Evaxion will present the findings at the International Herpesvirus Workshop in Montreal on July 12, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-004414), on July 01, 2026, and is solely responsible for the information contained therein.